MONROVIA, CA July 31, 2009
/24-7PressRelease/ -- Amy Scott-Billman, Vice President of Global Regulatory Strategy for Immunotherapeutics at GlaxoSmithKline Biologicals, is to give a keynote presentation concerning regulatory considerations & challenges for immunotherapeutic/diagnostic co-development at GTCbio's 5th Modern Drug Discovery & Development Summit, on October 14th-16th, 2009, in San Diego, CA.
Amy's presentation highlights GSK's approach to immunotherapy for cancer (Antigen-Specific Cancer Immunotherapeutics), challenges of co-development - biologic & companion in vitro diagnostics (screening assays & biomarkers), development/regulatory challenges/considerations for the biologic component, and development/regulatory challenges/considerations for the in vitro diagnostic component.
Amy is the Vice President of Global Regulatory Strategy for Immunotherapeutics at GlaxoSmithKline Biologicals (GSK Bio) where she manages a global staff responsible for all regulatory activities relevant to the development and commercialization of immunotherapeutic products for cancer and chronic disorder indications. Amy is also responsible for the regulatory aspects of in-licensing opportunities and for partnerships with external parties for the global development of companion in vitro diagnostics.
Prior to joining regulatory affairs at GSK in 1998, Amy served in GSK's World Wide Supply Operations as a Director of Quality Assurance & Compliance; supporting various business units including Research & Development, Biopharmaceuticals and Pharmaceuticals. Before joining GSK, Amy served for nearly 9 years at the Center for Biologics Evaluation and Research (CBER) at the US FDA in several capacities, including senior management, reviewer and inspector of biopharmaceutical manufacturing facilities. Amy received her B.S. in Microbiology from Pennsylvania State University and her M.S. in Biotechnology from Johns Hopkins University.
ABOUT GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.
GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.
Contact: GTCBIO (626) 256-6405, (626) 256-6460 fax, infogtcbio@gtcbio.com
---
Press release service and press release distribution provided by http://www.24-7pressrelease.com# # #
Read more Press Releases from Rania Hafez:- Allergan and CMO at Altheos to speak at Ocular Drug Discovery conference Feb 27-28, 2012 Las Vegas
- AstraZeneca, GSK to speak at Anti-infectives Partnering meeting Nov 7-8, Boston
- Glenn D. Prestwich to speak at 7th Modern Drug Discovery Summit Oct 19-21 2011 in San Diego, CA
- Vice President at Johnson and Johnson to speak at Modern Drug Summit Oct 19-21 2011 in San Diego, CA
- Biosimilars and FDA talk at 4th Protein Discovery & Therapeutics Conference Oct 19-21 in San Diego
- Dr. Joseph Joyce, Director At Merck & Co., To Speak At Vaccines Meeting On Nov. 7-8 In Boston, MA.
- Klarquist Sparkman to speak at 4th Protein Discovery & Therapeutics Meeting Oct 19-21 in San Diego
- Dr. Philip Dormitzer, Head at Novartis, to Speak at Vaccines Meeting on Nov. 7-8 in Boston, MA
- Klaus Mendla, Global Head at Boehringer to speak at CNS Partnering meeting Sept 22-23, San Francisco
- Dr. Kanta Subbarao, Chief at the NIH, to speak at vaccines meeting on Nov. 7-8 in Boston, MA
Other Press Release Headlines:
